dc.contributor.author |
Vokes, TJ |
|
dc.contributor.author |
Mannstadt, M |
|
dc.contributor.author |
Levine, MA |
|
dc.contributor.author |
Clarke, BL |
|
dc.contributor.author |
Lakatos, Péter |
|
dc.contributor.author |
Chen, K |
|
dc.contributor.author |
Piccolo, R |
|
dc.contributor.author |
Krasner, A |
|
dc.contributor.author |
Shoback, DM |
|
dc.contributor.author |
Bilezikian, JP |
|
dc.date.accessioned |
2020-03-18T10:12:53Z |
|
dc.date.available |
2020-03-18T10:12:53Z |
|
dc.date.issued |
2018 |
|
dc.identifier.citation |
journalVolume=103;journalIssueNumber=2;journalTitle=JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM;pagerange=722-731;journalAbbreviatedTitle=J CLIN ENDOCR METAB; |
|
dc.identifier.uri |
http://repo.lib.semmelweis.hu//handle/123456789/7181 |
|
dc.identifier.uri |
doi:10.1210/jc.2017-01471 |
|
dc.description.abstract |
Context: Reduced health-related quality of life (HRQoL) is common in patients with hypoparathyroidism on conventional therapy with calcium and active vitamin D supplements. Objective: To examine the effects of recombinant human parathyroid hormone (rhPTH[1-84]) on HRQoL as measured by the 36-Item Short Form Health Survey (SF-36) during the multinational, randomized, placebo-controlled REPLACE study. Patients: 122 adults with chronic hypoparathyroidism. Intervention(s): Following an optimization period when calcium and/or active vitamin D supplements were adjusted to reach target serum calcium levels (8.0-9.0 mg/dL; 2.0-2.2 mmol/L), patients were randomized to receive placebo (n=39) or rhPTH(1-84) (n=83) (starting dose 50 mug/day, could be titrated up to 100 mug/day); supplement doses were adjusted to maintain target serum calcium levels. Main Outcome Measure(s): Change from baseline (post-optimization, at randomization) to Week 24 in HRQoL as assessed by the SF-36v2 health survey. Results: Overall, the between-group differences were not statistically significant. However, in the rhPTH(1-84) group, there were significant improvements in the physical component summary score (P=0.004) and in body pain (P<0.05), general health (P<0.05), and vitality (P<0.001) domains as compared with baseline values. In the placebo group, there were no significant changes for any of the domains. The magnitude of change between 0 and 24 weeks in SF-36 scores was negatively correlated with baseline scores, such that patients with lower HRQoL at baseline were more likely to experience improvement in response to treatment. Conclusions: Treatment with rhPTH(1-84) may improve HRQoL in adults with hypoparathyroidism. |
|
dc.format.extent |
722-731 |
|
dc.relation.ispartof |
urn:issn:0021-972X |
|
dc.title |
Recombinant Human Parathyroid Hormone Effect on Health-Related Quality of Life in Adults With Chronic Hypoparathyroidism |
|
dc.type |
Journal Article |
|
dc.date.updated |
2019-07-07T11:10:03Z |
|
dc.language.rfc3066 |
en |
|
dc.rights.holder |
NULL |
|
dc.identifier.mtmt |
3296759 |
|
dc.identifier.wos |
WOS:000424937300043 |
|
dc.identifier.pubmed |
29099947 |
|
dc.contributor.department |
SE/AOK/K/I. Sz. Belgyógyászati Klinika |
|
dc.contributor.institution |
Semmelweis Egyetem |
|